Thomas Patrick Kelly - 28 Oct 2023 Form 4 Insider Report for Deciphera Pharmaceuticals, Inc.

Role
Chief Financial Officer
Signature
/s/ Jeffrey M. Held, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
28 Oct 2023
Net transactions value
-$27,833
Form type
4
Filing time
31 Oct 2023, 16:09:39 UTC
Previous filing
21 Jun 2023
Next filing
14 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DCPH Common Stock Award +8,244 +14% 65,384 28 Oct 2023 Direct F1
transaction DCPH Common Stock Sale $27,833 -2,316 -3.5% $12.02 63,068 30 Oct 2023 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 15, 2023, the Reporting Person was granted restricted stock units ("RSUs"), which vest upon the satisfaction of three performance criteria. On October 28, 2023, the Issuer's Compensation Committee confirmed that performance criteria two had been met, resulting in the vesting of 8,244 RSUs.
F2 This sale was to cover tax liabilities in the vesting of RSUs.